Moderna (MRNA) Price Target Lowered to $200 at Cowen, Analyst Cites Development Risks of Flu, RSV and CMV Programs

January 27, 2022 6:42 AM EST
Get Alerts MRNA Hot Sheet
Price: $137.62 +1.01%

Rating Summary:
    8 Buy, 12 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 3 | Down: 3 | New: 34
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Cowen analyst Tyler Van Buren lowers his price target on Moderna (NASDAQ: MRNA) to $200 from $250, while maintaining a "Market Perform" rating, as he models higher risks associated with development of the flu, RSV, and CMV programs.

The analyst quotes: "Our Q4 EPS estimate is now $10.00 (+30% Q/Q). Our (2) rating remains, but we are lowering our DCF-based price target from $250 per share to $200 per share, as we increase our discount rate to a more appropriate 13% to account for the development risk with the flu, RSV, and CMV programs."

Shares of Moderna are trading over 2% higher in pre-market, in the $160 area.

Written by Vlad Schepkov | [email protected]

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Hot Comments, Trader Talk

Related Entities

Cowen & Co, Vlad Schepkov